If approved, the drug would be indicated for patients with a body mass index of 27 or greater with weight-related comorbidities such as hypertension, type 2 diabetes, dyslipidemia, or central adiposity. The agency is expected to issue its decision by …
See all stories on this topic »
We LOVE you so.. how about liking us on Facebook?..
Powered By Facebook Like Post Plugin